

15 July 2010

Company Announcements Office  
Australian Stock Exchange  
PO Box H224  
Australia Square  
SYDNEY NSW 2000

Dear Sir/Madam

**APPENDIX 3Y**

Please find attached Appendix 3Y for the acquisition of 55,000 shares by Avita Medical's Chief Executive Officer, Mr William Dolphin. The Appendix 3Y also notes 184,522 ordinary shares noted as a carry-over of shares acquired by Mr William Dolphin in Visiomed Limited pre-merger between Clinical Cell Culture Ltd. As a result of an administrative oversight by the Company, these shares were overlooked from previous the disclosure by the Company.

- ENDS -

FOR FURTHER INFORMATION PLEASE CONTACT:

Gabriel Chiappini  
Avita Medical Limited  
Tel: +61 8 9486 1644  
[Gabriel@laurus.net.au](mailto:Gabriel@laurus.net.au)

**ABOUT AVITA MEDICAL LIMITED**

Avita Medical Limited ([www.avitamedical.com](http://www.avitamedical.com)) is a publicly listed, global medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a wide range of wounds, scars and skin defects. Using proprietary tissue - culture/collection technology, the company is able to provide innovative treatment solutions derived from the patient's own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.

ReCell® is a stand-alone, rapid cell harvesting device that enables surgeons to treat skin defects using the patient's own cells. The surgeon can prepare a small quantity of cells within 30 minutes on site, replacing the need for skin grafts and obviating the requirement for culturing laboratories. ReCell® has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is gaining acceptance in a number of indications including Vitiligo, a common skin pigmentation disease.

ReCell® is patented, CE marked for the EU and TGA registered in Australia

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

Name of entity	<b>Avita Medical Limited</b>
ABN	<b>28 058 466 523</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	<b>William Ford Dolphin</b>
Date of last notice	<b>9 March 2010</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Direct or indirect interest	<b>Indirect</b>
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	William & Alison Dolphin <The Dolphin Family Super Fund>
Date of change	<b>12 July 2010</b>
No. of securities held prior to change	<b>Indirect</b> - William & Alison Dolphin <The Dolphin Family Super Fund> 164,047 ordinary shares 571,429 unlisted options, expiring 28/2/2011, exercise price \$0.28 214,286 unlisted options, expiring 28/2/2011, exercise price \$0.36 <b>Direct</b> – 184,522 ordinary shares 5,000,000 unlisted options, expiring 14/11/2014, exercise price \$0.14
Class	ORD shares
Number acquired	55,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.11 per share

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

No. of securities held after change	<p><b>Indirect - William &amp; Alison Dolphin &lt;The Dolphin Family Super Fund&gt;</b></p> <p>219,047 ordinary shares  571,429 unlisted options, expiring 28/2/2011, exercise price \$0.28  214,286 unlisted options, expiring 28/2/2011, exercise price \$0.36</p> <p><b>Direct</b>  184,522 ordinary shares  5,000,000 unlisted options, expiring 14/11/2014, exercise price \$0.14</p>
<p><b>Nature of change</b>  Example: on-market trade, off- market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	On-market

**Part 2 – Change of director's interests in contracts**

Detail of contract	<b>Not Applicable</b>
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<p>No. and class of securities to which interest related prior to change</p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	
Interest acquired	
Interest disposed	
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and an estimated valuation</p>	
Interest after change	

---

+ See chapter 19 for defined terms.